Share on LinkedInShare on LinkedIn

ARTICLE · 05 OCTOBER 2022

COVID-19: Is The IP Truce Over?

The COVID-19 pandemic brought with it something of an IP truce, with major pharmaceutical companies seemingly happy to co-exist.

South AfricaIntellectual Property

The COVID-19 pandemic brought with it something of an IP truce, with major pharmaceutical companies seemingly happy to co-exist. However, it now seems that a battle is about to commence with three of the major players in the COVID-19 vaccine industry now in dispute.

Moderna v Pfizer/BioNTech

Moderna

Moderna, a company based in Cambridge, Massachusetts, USA (and founded as recently as 2010) was an early developer of the mRNA technology. The company's vaccine comprises mRNA that expresses a viral protein and generates an immune response training the body to fight off a real virus when it comes into contact with it.

Moderna obtained approval for its vaccine in a matter of months when the US Food and Drug Administration, ("FDA") granted "emergency use authorisation" for the company's COVID-19 vaccine in December 2020. At the same time, the FDA had already also granted authorisation to Pfizer/BioNTech (just one week earlier).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from